Literature DB >> 12719863

[Practice experience with topical calcineurin inhibitors].

J Lübbe1.   

Abstract

The clinical experience with topical calcineurin inhibitors in the field is still rudimentary, if compared to our knowledge of topical corticosteroids. This is especially true for the long-term effects. The systemic transcutaneous absorption that occurs during the therapy of atopic dermatitis is quantitatively irrelevant. However, in the setting of permanent disruption of the skin barrier, as may be encountered in rare Genodermatoses, but as well in cases that do not respond to therapy, continued treatment my result in clinically relevant blood levels. Side effects of topical calcineurin inhibitors may be separated into two groups, i.e. local intolerance reactions, and skin infections. While the typical burning sensation of the newly treated skin is ephemeral, local alcohol intolerance, albeit less frequent, will persist throughout the treatment period. Regarding skin infections, Eczema herpeticatum seems to be the only serious complication; adequate preventive will further reduce the risk of this rare complication.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719863     DOI: 10.1007/s00105-003-0527-0

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  47 in total

1.  Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment.

Authors:  J Lübbe; C C Pournaras; J H Saurat
Journal:  Dermatology       Date:  2000       Impact factor: 5.366

2.  FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.

Authors:  T Kino; H Hatanaka; M Hashimoto; M Nishiyama; T Goto; M Okuhara; M Kohsaka; H Aoki; H Imanaka
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

3.  Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment.

Authors:  H Aoyama; N Tabata; M Tanaka; Y Uesugi; H Tagami
Journal:  Br J Dermatol       Date:  1995-09       Impact factor: 9.302

4.  Fibronectin and fibrinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin.

Authors:  S H Cho; I Strickland; M Boguniewicz; D Y Leung
Journal:  J Allergy Clin Immunol       Date:  2001-08       Impact factor: 10.793

Review 5.  Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis.

Authors:  I Bekersky; W Fitzsimmons; A Tanase; R M Maher; E Hodosh; I Lawrence
Journal:  J Am Acad Dermatol       Date:  2001-01       Impact factor: 11.527

6.  Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety.

Authors:  N A Soter; A B Fleischer; G F Webster; E Monroe; I Lawrence
Journal:  J Am Acad Dermatol       Date:  2001-01       Impact factor: 11.527

Review 7.  Tacrolimus: the drug for the turn of the millennium?

Authors:  T Ruzicka; T Assmann; B Homey
Journal:  Arch Dermatol       Date:  1999-05

8.  Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease.

Authors:  D H Casson; M Eltumi; S Tomlin; J A Walker-Smith; S H Murch
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

9.  Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis.

Authors:  Sakari Reitamo; Edwin J M Van Leent; Vincent Ho; John Harper; Thomas Ruzicka; Kirsti Kalimo; Frédéric Cambazard; Malcolm Rustin; Alain Taïeb; David Gratton; Daniel Sauder; Graham Sharpe; Catherine Smith; Michael Jünger; Yves de Prost
Journal:  J Allergy Clin Immunol       Date:  2002-03       Impact factor: 10.793

10.  Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.

Authors:  Ulrich Wahn; Jan D Bos; Mark Goodfield; Ruggero Caputo; Kim Papp; Ahmed Manjra; Attila Dobozy; Carle Paul; Stephen Molloy; Thomas Hultsch; Michael Graeber; Robert Cherill; Yves de Prost
Journal:  Pediatrics       Date:  2002-07       Impact factor: 7.124

View more
  2 in total

Review 1.  [Systemic therapy of atopic dermatitis].

Authors:  A Heratizadeh; K Breuer; A Kapp; T Werfel
Journal:  Hautarzt       Date:  2003-10       Impact factor: 0.751

Review 2.  [Eczema herpeticatum].

Authors:  S Wetzel; A Wollenberg
Journal:  Hautarzt       Date:  2004-07       Impact factor: 1.198

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.